Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete
Ayvakyt avapritinib Advanced Systemic Mastocytosis Active
Azarga Brinzolamide and timolol maleate suspension Glaucoma and ocular hypertension List in a similar manner to other drugs in class Complete
Azilect Rasagiline mesylate Parkinson's disease Do not list Complete
Azilect Rasagiline mesylate Parkinson's disease N/A Complete
Balversa erdafitinib locally advanced unresectable or metastatic urothelial carcinoma (UC) Active
Banzel Rufinamide Lennox-Gastaut syndrome List with clinical criteria and/or conditions Complete
Baqsimi glucagon Severe hypoglycemic reactions Reimburse with clinical criteria and/or conditions Complete
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete
Basaglar Insulin glargine Diabetes mellitus, type 1; diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete